EPIRUS Biopharmaceuticals

EPIRUS Biopharmaceuticals, Inc. is a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS aims to improve global patient access to vital, cost-effective medications. The company's current biosimilar pipeline includes: BOW015, BOW050, BOW070, BOW080, BOW090, BOW100.